Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 648

1.

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF.

Lung Cancer. 2019 Nov 4;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. [Epub ahead of print]

PMID:
31739184
2.

Analysis on biological importance of antiseptic drug, O-Benzyl hydroxylamine, by the application of spectroscopic and theoretical tools.

Manthiri AA, George G, Ramalingam S, Aarthi R.

Heliyon. 2019 Sep 13;5(9):e02447. doi: 10.1016/j.heliyon.2019.e02447. eCollection 2019 Sep.

3.

Mcl-1 interacts with Akt to promote lung cancer progression.

Chen G, Park D, Magis AT, Behera M, Ramalingam SS, Owonikoko TK, Sica GL, Ye K, Zhang C, Chen Z, Curran WJ, Deng X.

Cancer Res. 2019 Oct 29. pii: canres.0950.2019. doi: 10.1158/0008-5472.CAN-19-0950. [Epub ahead of print]

PMID:
31662324
4.

Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.

Kwegyir-Afful AK, Ramalingam S, Ramamurthy VP, Purushottamachar P, Murigi FN, Vasaitis TS, Huang W, Kane MA, Zhang Y, Ambulos N, Tiwari S, Srivastava P, Nnane IP, Hussain A, Qiu Y, Weber DJ, Njar VCO.

Cancers (Basel). 2019 Oct 24;11(11). pii: E1637. doi: 10.3390/cancers11111637.

5.

Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.

Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA.

Cancer. 2019 Oct 24. doi: 10.1002/cncr.32576. [Epub ahead of print]

PMID:
31648379
6.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334-9. doi: 10.1016/j.jtho.2019.09.009. [Epub ahead of print]

7.

Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing.

Acharya S, Mishra A, Paul D, Ansari AH, Azhar M, Kumar M, Rauthan R, Sharma N, Aich M, Sinha D, Sharma S, Jain S, Ray A, Jain S, Ramalingam S, Maiti S, Chakraborty D.

Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):20959-20968. doi: 10.1073/pnas.1818461116. Epub 2019 Sep 30.

PMID:
31570623
8.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.

PMID:
31562796
9.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.

Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23.

PMID:
31549216
10.

Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.

Vishwanathan K, Cantarini M, So K, Masson E, Fetterolf J, Ramalingam SS, Harvey RD.

Clin Transl Sci. 2019 Sep 9. doi: 10.1111/cts.12688. [Epub ahead of print]

PMID:
31498564
11.

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.

Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD.

BMC Cancer. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7.

12.

Verifying measurements of residual calcium content in demineralised cortical bone.

Ariffin AF, Yusof N, Mohd S, Rahman SA, Ramalingam S, Mansor A, Min NG.

Cell Tissue Bank. 2019 Dec;20(4):527-534. doi: 10.1007/s10561-019-09785-4. Epub 2019 Aug 28.

PMID:
31456097
13.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.

PMID:
31439584
14.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J.

Lancet Oncol. 2019 Oct;20(10):1395-1408. doi: 10.1016/S1470-2045(19)30407-3. Epub 2019 Aug 14.

PMID:
31422028
15.

Enlarged and Enhancing Optic Nerves in Advanced Glial Fibrillary Acidic Protein Meningoencephalomyelitis.

White D, Mollan SP, Ramalingam S, Nagaraju S, Hayton T, Jacob S.

J Neuroophthalmol. 2019 Sep;39(3):411-415. doi: 10.1097/WNO.0000000000000842.

PMID:
31397693
16.

CRISPR-Cas9 Probing of Infectious Diseases and Genetic Disorders.

Ramalingam S, Thangavel S.

Indian J Pediatr. 2019 Jul 31. doi: 10.1007/s12098-019-03037-9. [Epub ahead of print] Review.

PMID:
31367975
17.

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.

Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH.

J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30.

PMID:
31361535
18.

Lateral Periodontal Cyst Treated with Enucleation and Guided Bone Regeneration: A Report of a Case and a Review of Pertinent Literature.

Ramalingam S, Alrayyes YF, Almutairi KB, Bello IO.

Case Rep Dent. 2019 Jul 8;2019:4591019. doi: 10.1155/2019/4591019. eCollection 2019.

19.

Acetylation regulates ribonucleotide reductase activity and cancer cell growth.

Chen G, Luo Y, Warncke K, Sun Y, Yu DS, Fu H, Behera M, Ramalingam SS, Doetsch PW, Duong DM, Lammers M, Curran WJ, Deng X.

Nat Commun. 2019 Jul 19;10(1):3213. doi: 10.1038/s41467-019-11214-9.

20.

Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.

Deng L, Qian G, Zhang S, Zheng H, Fan S, Lesinski GB, Owonikoko TK, Ramalingam SS, Sun SY.

Oncogene. 2019 Aug;38(35):6270-6282. doi: 10.1038/s41388-019-0877-4. Epub 2019 Jul 17.

PMID:
31316145
21.

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India.

Munir A, Kumar N, Ramalingam SB, Tamilzhalagan S, Shanmugam SK, Palaniappan AN, Nair D, Priyadarshini P, Natarajan M, Tripathy S, Ranganathan UD, Peacock SJ, Parkhill J, Blundell TL, Malhotra S.

Sci Rep. 2019 Jul 16;9(1):10283. doi: 10.1038/s41598-019-46756-x.

22.

Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.

Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, Saba NF, Pakkala S, Patel PR, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M, Higgins KA.

Clin Lung Cancer. 2019 Nov;20(6):484-493.e6. doi: 10.1016/j.cllc.2019.06.014. Epub 2019 Jun 18.

PMID:
31296433
23.

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.

Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3.

24.

Improving knowledge of doctors and paramedics through effective bone procurement workshop: A cognitive approach.

Mohd S, Yusof N, Lai LL, Hossain MG, Ramalingam S, Hamid SSA, Ng WM, Mansor A.

BMC Med Educ. 2019 Jul 1;19(1):238. doi: 10.1186/s12909-019-1685-9.

25.

Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.

Bhargava N, Jaitly S, Goswami SG, Jain S, Chakraborty D, Ramalingam S.

Stem Cell Res. 2019 Aug;39:101484. doi: 10.1016/j.scr.2019.101484. Epub 2019 Jun 14.

26.

Corrigendum to "Comparative study of the physicochemical, nutritional, and antioxidant properties of some commercial refined and non-centrifugal sugars". [Food Research International 109 (2018) 614-625].

Lee JS, Ramalingam S, Jo IG, Kwon YS, Bahuguna A, Oh YS, Kwon OJ, Kim M.

Food Res Int. 2019 Aug;122:563. doi: 10.1016/j.foodres.2018.06.037. Epub 2018 Jun 28. No abstract available.

PMID:
31229113
27.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.

28.

Antioxidant potential of theaflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin - induced diabetic rats.

Gothandam K, Ganesan VS, Ayyasamy T, Ramalingam S.

Redox Rep. 2019 Dec;24(1):41-50. doi: 10.1080/13510002.2019.1624085.

PMID:
31142215
29.

End-of-Life Practices in Rural South India: SocioCultural Determinants.

Ramalingam S, Ganesan S.

Indian J Palliat Care. 2019 Apr-Jun;25(2):224-227. doi: 10.4103/IJPC.IJPC_173_18.

30.

DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Teneng I, Picchi MA, Leng S, Dagucon CP, Ramalingam S, Tellez CS, Belinsky SA.

DNA Repair (Amst). 2019 Jul;79:1-9. doi: 10.1016/j.dnarep.2019.04.006. Epub 2019 Apr 27.

PMID:
31055244
31.

Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1's elimination during colon cancer development and progression.

Roy BC, Ahmed I, Ramalingam S, Jala V, Haribabu B, Ramamoorthy P, Ashcraft J, Valentino J, Anant S, Sampath V, Umar S.

Oncotarget. 2019 Mar 22;10(24):2340-2354. doi: 10.18632/oncotarget.26684. eCollection 2019 Mar 22.

32.

Pleotropic role of RNA binding protein CELF2 in autophagy induction.

New J, Subramaniam D, Ramalingam S, Enders J, Sayed AAA, Ponnurangam S, Standing D, Ramamoorthy P, O'Neil M, Dixon DA, Saha S, Umar S, Gunewardena S, Jensen RA, Thomas SM, Anant S.

Mol Carcinog. 2019 Aug;58(8):1400-1409. doi: 10.1002/mc.23023. Epub 2019 Apr 24.

PMID:
31020708
33.

Phosphorene-gold nanocomposite based microfluidic aptasensor for the detection of okadaic acid.

Ramalingam S, Chand R, Singh CB, Singh A.

Biosens Bioelectron. 2019 Jun 15;135:14-21. doi: 10.1016/j.bios.2019.03.056. Epub 2019 Apr 5.

PMID:
30981975
34.

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.

Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X.

Mol Cancer. 2019 Apr 10;18(1):85. doi: 10.1186/s12943-019-1012-4.

35.

Characterisation of graphene electrodes for microsystems and microfluidic devices.

Del Rosso M, Brodie CH, Ramalingam S, Cabral DM, Pensini E, Singh A, Collier CM.

Sci Rep. 2019 Apr 8;9(1):5773. doi: 10.1038/s41598-019-42108-x.

36.

Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies.

Sabarimurugan S, Kumarasamy C, Madurantakam Royam M, Lakhotiya K, Kodiveri Muthukaliannan G, Ramalingam S, Jayaraj R.

Medicine (Baltimore). 2019 Mar;98(12):e14570. doi: 10.1097/MD.0000000000014570.

37.

Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity.

Sukhatme VV, Ramalingam SS, Ahmed R, Sukhatme VP.

Cancer J. 2019 Mar/Apr;25(2):88-99. doi: 10.1097/PPO.0000000000000368.

PMID:
30896530
38.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

PMID:
30876831
39.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.

J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.

PMID:
30872388
40.

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations.

Shi P, Zhang S, Zhu L, Qian G, Ren H, Ramalingam SS, Chen M, Sun SY.

Transl Oncol. 2019 May;12(5):705-713. doi: 10.1016/j.tranon.2019.02.006. Epub 2019 Mar 9.

41.

Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.

Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, Chen Z, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF.

Head Neck. 2019 May;41(5):1490-1498. doi: 10.1002/hed.25379. Epub 2019 Mar 5. Review.

PMID:
30835900
42.

The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.

Ramalingam S, Ramamurthy VP, Gediya LK, Murigi FN, Purushottamachar P, Huang W, Choi EY, Zhang Y, Vasaitis TS, Kane MA, Lapidus RG, Njar VCO.

Cancers (Basel). 2019 Mar 3;11(3). pii: E299. doi: 10.3390/cancers11030299.

43.

A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.

Gill HS, Ramalingam SS.

Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996. [Epub ahead of print] No abstract available.

PMID:
30825394
44.

Clinical prognostic model for older patients with advanced non-small cell lung cancer.

Ganti AK, Wang X, Stinchcombe TE, Wang Y, Bradley J, Cohen HJ, Kelly K, Paulus R, Ramalingam SS, Vokes EE, Pang H.

J Geriatr Oncol. 2019 Jul;10(4):555-559. doi: 10.1016/j.jgo.2019.02.007. Epub 2019 Feb 21.

PMID:
30797707
45.

The CRISPR/Cas9 System for Targeted Genome Engineering in Free-Living Fungi: Advances and Opportunities for Lichenized Fungi.

Shanmugam K, Ramalingam S, Venkataraman G, Hariharan GN.

Front Microbiol. 2019 Feb 7;10:62. doi: 10.3389/fmicb.2019.00062. eCollection 2019. Review.

46.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Apr;42(4):331-336. doi: 10.1097/COC.0000000000000524.

PMID:
30789414
47.

Periodontal therapy as an adjunctive modality for HbA1c reduction in type-2 diabetic patients.

Sundar C, Ramalingam S, Mohan V, Pradeepa R, Ramakrishnan MJ.

J Educ Health Promot. 2018 Dec 28;7:152. doi: 10.4103/jehp.jehp_66_18. eCollection 2018.

48.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
49.

Anti-dengue activity of Andrographis paniculata extracts and quantification of dengue viral inhibition by SYBR green reverse transcription polymerase chain reaction.

Ramalingam S, Karupannan S, Padmanaban P, Vijayan S, Sheriff K, Palani G, Krishnasamy KK.

Ayu. 2018 Apr-Jun;39(2):87-91. doi: 10.4103/ayu.AYU_144_17.

50.

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2019 May;14(5):876-889. doi: 10.1016/j.jtho.2019.01.020. Epub 2019 Feb 5.

PMID:
30735816

Supplemental Content

Loading ...
Support Center